Matches in SemOpenAlex for { <https://semopenalex.org/work/W2487613987> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2487613987 endingPage "2514" @default.
- W2487613987 startingPage "2514" @default.
- W2487613987 abstract "2514 Background: ONC201 is an orally active, first-in-class small molecule activator of the integrated stress response that selectively upregulates ATF4 to trigger tumor cell death. Preclinical studies have established the compelling antitumor efficacy of the small molecule in a range of advanced solid tumors as well as its excellent safety profile in animals. A first-in-human phase I study of ONC201 was conducted to determine its recommended phase II dose (RP2D) in patients with advanced solid tumors. Methods: This open-label study treated 10 patients during the single-patient cohort dose escalation portion of the trial. The human starting dose was 125mg, which represents 1/10th of the no-adverse-adverse-effect-level in animal toxicology studies using standard allometric conversion. Results: The RP2D was defined as 625 mg and no Grade > 1 drug-related adverse events occurred on this trial, which enrolled patients at increasing dose levels of 125mg, 250mg, 375mg, 500mg, and finally 625mg. Pharmacokinetic analysis revealed saturation of absorption at 375mg, suggesting dose escalation above 625mg was not warranted. The terminal half-life was 9.6 hours, Cmax values ranged from 1.5 - 7.5 ug/mL (~3.9-19.4 uM), and the AUC was 25 hr ug/L. Prolonged induction of caspase-cleaved keratin 18 and induction of TRAIL was observed in serum samples. Eight of 10 patients had stable disease and one patient with endometrial cancer underwent a mixed response. 17 of 25 additional patients have been accrued in an ongoing expansion phase. The available results from the expansion cohort confirm the excellent safety, and the pharmacokinetic and pharmacodynamic profiles of ONC201 at the recommended phase II dose of 625mg every three weeks. Conclusions: This study demonstrates that ONC201 is well tolerated and active at an oral dose of 625mg, warranting further evaluation in lead indications. Clinical trial information: NCT02250781." @default.
- W2487613987 created "2016-08-23" @default.
- W2487613987 creator A5008547275 @default.
- W2487613987 creator A5012047866 @default.
- W2487613987 creator A5019301771 @default.
- W2487613987 creator A5036916387 @default.
- W2487613987 creator A5041474007 @default.
- W2487613987 creator A5047620686 @default.
- W2487613987 creator A5053602981 @default.
- W2487613987 creator A5055837818 @default.
- W2487613987 creator A5063899863 @default.
- W2487613987 creator A5065113263 @default.
- W2487613987 creator A5071773606 @default.
- W2487613987 creator A5081735541 @default.
- W2487613987 creator A5089654215 @default.
- W2487613987 creator A5090739964 @default.
- W2487613987 date "2016-05-20" @default.
- W2487613987 modified "2023-10-03" @default.
- W2487613987 title "First-in-human trial of ONC201 in patients with refractory solid tumors." @default.
- W2487613987 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.2514" @default.
- W2487613987 hasPublicationYear "2016" @default.
- W2487613987 type Work @default.
- W2487613987 sameAs 2487613987 @default.
- W2487613987 citedByCount "2" @default.
- W2487613987 countsByYear W24876139872018 @default.
- W2487613987 countsByYear W24876139872023 @default.
- W2487613987 crossrefType "journal-article" @default.
- W2487613987 hasAuthorship W2487613987A5008547275 @default.
- W2487613987 hasAuthorship W2487613987A5012047866 @default.
- W2487613987 hasAuthorship W2487613987A5019301771 @default.
- W2487613987 hasAuthorship W2487613987A5036916387 @default.
- W2487613987 hasAuthorship W2487613987A5041474007 @default.
- W2487613987 hasAuthorship W2487613987A5047620686 @default.
- W2487613987 hasAuthorship W2487613987A5053602981 @default.
- W2487613987 hasAuthorship W2487613987A5055837818 @default.
- W2487613987 hasAuthorship W2487613987A5063899863 @default.
- W2487613987 hasAuthorship W2487613987A5065113263 @default.
- W2487613987 hasAuthorship W2487613987A5071773606 @default.
- W2487613987 hasAuthorship W2487613987A5081735541 @default.
- W2487613987 hasAuthorship W2487613987A5089654215 @default.
- W2487613987 hasAuthorship W2487613987A5090739964 @default.
- W2487613987 hasConcept C111113717 @default.
- W2487613987 hasConcept C112705442 @default.
- W2487613987 hasConcept C121608353 @default.
- W2487613987 hasConcept C126322002 @default.
- W2487613987 hasConcept C143998085 @default.
- W2487613987 hasConcept C197934379 @default.
- W2487613987 hasConcept C22979827 @default.
- W2487613987 hasConcept C2775930923 @default.
- W2487613987 hasConcept C2779744173 @default.
- W2487613987 hasConcept C530470458 @default.
- W2487613987 hasConcept C71924100 @default.
- W2487613987 hasConcept C90924648 @default.
- W2487613987 hasConcept C98274493 @default.
- W2487613987 hasConceptScore W2487613987C111113717 @default.
- W2487613987 hasConceptScore W2487613987C112705442 @default.
- W2487613987 hasConceptScore W2487613987C121608353 @default.
- W2487613987 hasConceptScore W2487613987C126322002 @default.
- W2487613987 hasConceptScore W2487613987C143998085 @default.
- W2487613987 hasConceptScore W2487613987C197934379 @default.
- W2487613987 hasConceptScore W2487613987C22979827 @default.
- W2487613987 hasConceptScore W2487613987C2775930923 @default.
- W2487613987 hasConceptScore W2487613987C2779744173 @default.
- W2487613987 hasConceptScore W2487613987C530470458 @default.
- W2487613987 hasConceptScore W2487613987C71924100 @default.
- W2487613987 hasConceptScore W2487613987C90924648 @default.
- W2487613987 hasConceptScore W2487613987C98274493 @default.
- W2487613987 hasIssue "15_suppl" @default.
- W2487613987 hasLocation W24876139871 @default.
- W2487613987 hasOpenAccess W2487613987 @default.
- W2487613987 hasPrimaryLocation W24876139871 @default.
- W2487613987 hasRelatedWork W1971830765 @default.
- W2487613987 hasRelatedWork W1973811753 @default.
- W2487613987 hasRelatedWork W1984288543 @default.
- W2487613987 hasRelatedWork W1997101420 @default.
- W2487613987 hasRelatedWork W2000547109 @default.
- W2487613987 hasRelatedWork W2068691394 @default.
- W2487613987 hasRelatedWork W2477866235 @default.
- W2487613987 hasRelatedWork W2617001846 @default.
- W2487613987 hasRelatedWork W3097307756 @default.
- W2487613987 hasRelatedWork W3205517375 @default.
- W2487613987 hasVolume "34" @default.
- W2487613987 isParatext "false" @default.
- W2487613987 isRetracted "false" @default.
- W2487613987 magId "2487613987" @default.
- W2487613987 workType "article" @default.